You‐Kuan Yin

Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients

Jidong Jia, Jinlin Hou, You‐Kuan Yin, Deming Tan et autres

cn, gb, ch (code pays fourni par la source)

Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine

Rifaat Safadi, Qing Xie, Yagang Chen, You‐Kuan Yin et autres

BACKGROUND: Telbivudine showed greater antiviral suppression than lamivudine in phase II and III clinical trials. AIMS: The present phase IIIb, randomized, double-blind, multicentre global trial assessed the antiviral efficacy and safety of telbivudine switch in chronic hepatitis B (CHB) patients who exhibited …

il, cn, kr, ch (code pays fourni par la source)

Prevalence of basal core promoter and precore mutations in Chinese chronic hepatitis B patients and correlation with serum HBeAG titers

Yanli Qin, Jiming Zhang, Richeng Mao, Hongying Guo et autres

The A1762T and G1764A mutations in the basal core promoter (BCP) region and the G1896A mutation in the precore (PC) region of hepatitis B virus (HBV) genome are found commonly in HBeAg-negative patients. Experiments in vitro suggest that BCP and PC mutation …

cn, us (code pays fourni par la source)

Spontaneous HBeAg seroconversion and loss of hepatitis B virus DNA after acute flare due to development of drug resistant mutants during entecavir monotherapy

Richeng Mao, You‐Kuan Yin, Yanli Qin, Xianghui Wu et autres

AIMS: Patients with chronic hepatitis B virus (HBV) infection under entecavir (ETV) treatment develop resistant mutants with viral rebound. Here, we report an interesting case of spontaneous loss of HBV-DNA and seroconversion following an acute flare after the development of ETV-resistant mutants. …

cn, de (code pays fourni par la source)

Fever of unknown origin: revisit of 142 cases in a tertiary Chinese hospital.

Yuekai Hu, Hongzhou Lu, Yunzhi Zhang, Weimin Jiang et autres

To investigate the causes of fever of unknown origin (FUO), we analyzed the clinical data on 142 patients with FUO admitted to our department from January 2002 to December 2003. After various examinations and specific treatment, a definitive diagnosis was reached in …

cn (code pays fourni par la source)

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial

Jinlin Hou, You‐Kuan Yin, Dao-zhen Xu, Deming Tan et autres

UNLABELLED: Chronic hepatitis B and its life-threatening sequelae are highly prevalent in China. There is a need for effective new therapies to suppress hepatitis B virus (HBV) replication and ameliorate liver disease. In this study, we compared the efficacy of telbivudine, a …

cn, us (code pays fourni par la source)

[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].

Jidong Jia, Jinlin Hou, You‐Kuan Yin, Dao-zhen Xu et autres

OBJECTIVES: To investigate the possibilities of an association between the degrees of HBV suppression with nucleoside treatments at week 24 and week 52 in hepatitis B patients and to find a useful predictor for treatment efficacy. METHODS: In this phase III, double-blind, …

cn (code pays fourni par la source)

[Advances in research of hepatitis B virus resistance to adefovir].

Richeng Mao, You‐Kuan Yin, Jiming Zhang

核苷(酸)类似物类抗HBV药物的问世是慢性乙型肝炎治疗史上的里程碑之一.这类药物的广泛应用在为慢性乙型肝炎患者带来福音的同时,也带来了较为严重的耐药问题.由于HBV的复制需通过逆转录机制,而HBV聚合酶缺乏校正的功能,因此,HBV比其他DNA病毒更容易发生变异.随着治疗时间的延长,对核苷类药物耐药的变异株被选择出来,且逐渐成为优势毒株,在临床上表现为HBV DNA水平的反弹,有些患者会出现病情的加重.阿德福韦自2002年上市以来已广泛应用于临床,随着时间的延长,HBV对阿德福韦的耐药率也逐渐增加,引起了人们的广泛重视。

cn (code pays fourni par la source)

[The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy].

Yanli Qin, Jiming Zhang, Yuxian Huang, Richeng Mao et autres

OBJECTIVE: To study the resistant rate of hepatitis B virus (HBV) to ADV and the dynamic evolution of HBV in lamivudine (Lam)-resistant chronic hepatitis B (CHB) patients. METHODS: Twenty-three Lam-resistant CHB patients were assigned to a 10mg/d ADV monotherapy for 68-116 weeks. …

cn (code pays fourni par la source)

[A double-blind, randomized, lamivudine-controlled clinical trial of DAIDING (adefovir dipivoxil) for lamivudine-resistant patients with chronic hepatitis B].

Yuming Wang, Yaokai Chen, Dazhi Zhang, Lei Bing-jun et autres

OBJECTIVE: To investigate the efficacy and safety of adefovir dipivoxil (ADV, DAIDING) for Chinese chronic hepatitis B patients with lamivudine (LAM) resistance. METHODS: This study was a multicenter, double-blind clinical trial. 209 chronic hepatitis B patients with LAM resistance were randomly put …

cn (code pays fourni par la source)

Fatal liver failure with the emergence of hepatitis B surface antigen variants with multiple stop mutations after discontinuation of lamivudine therapy

Jiming Zhang, Xinyu Wang, Yuxian Huang, You‐Kuan Yin et autres

Treatment of chronic hepatitis B virus (HBV) infection with lamivudine is effective and well-tolerated. However, discontinuation of the treatment is associated frequently with acute exacerbation of liver diseases. A patient suffering from acute liver failure after discontinuation of lamivudine treatment is described. …

cn, de (code pays fourni par la source)

Cryptococcal Antigen Test Revisited: Significance for Cryptococcal Meningitis Therapy Monitoring in a Tertiary Chinese Hospital

Hongzhou Lu, Yingjie Zhou, You‐Kuan Yin, Xinhua Weng

For a total of 29 non-human immunodeficiency virus 1 cryptococcal meningitis cases, titer changes in the latex agglutination test before and after therapy were reviewed along with clinical manifestations, laboratory findings, and therapy regimens. The cryptococcal antigen titer decreased for every case …

cn (code pays fourni par la source)